Review article · 2023 · Open access
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Journal of Biomedical Science, 30(1), 83 · Published 2 October 2023 · DOI 10.1186/s12929-023-00976-6
In brief
“Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update” is a 2023 review article by Li‐Kai Huang and 3 co-authors, published in Journal of Biomedical Science. OpenAlex counts 282 citations as of 15 November 2026, which puts it in the top 4% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Journal of Biomedical Science.
- Citations
- 282
- Most cited in
- 2024 (109)
- Field-weighted impact
- 7.69
- References
- 84
- Authors
- 4
Abstract
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury. Clinical trials focusing on new drugs for AD were documented in 2020, but subsequent developments have emerged since then. Notably, the US-FDA has approved Aducanumab and Lecanemab, both antibodies targeting amyloid, marking the end of a nearly two-decade period without new AD drugs. In this comprehensive report, we review all trials listed in clinicaltrials.gov, elucidating their underlying mechanisms and study designs. Ongoing clinical trials are investigating numerous promising new drugs for AD. The main trends in these trials involve pathophysiology-based, disease-modifying therapies and the recruitment of participants in earlier stages of the disease. These trends underscore the significance of conducting fundamental research on pathophysiology, prevention, and intervention prior to the occurrence of brain damage caused by AD.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Huang, L., Kuan, Y., Lin, H.-W., & Hu, C. (2023). Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update. Journal of Biomedical Science, 30(1), 83. https://doi.org/10.1186/s12929-023-00976-6
MLA 9
Huang, Li‐Kai, et al. “Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update.” Journal of Biomedical Science, vol. 30, no. 1, 2023, p. 83. https://doi.org/10.1186/s12929-023-00976-6.
Chicago
Huang, Li‐Kai, Yi‐Chun Kuan, Ho-Wei Lin, and Chaur‐Jong Hu. 2023. “Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update.” Journal of Biomedical Science 30 (1): 83. https://doi.org/10.1186/s12929-023-00976-6.
Harvard
Huang, L. et al. (2023) ‘Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update’, Journal of Biomedical Science, 30(1), p. 83. doi:10.1186/s12929-023-00976-6.
IEEE
L. Huang, Y. Kuan, H.-W. Lin, and C. Hu, “Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update,” Journal of Biomedical Science, vol. 30, no. 1, p. 83, 2023, doi: 10.1186/s12929-023-00976-6.
BibTeX
@article{huang2023clinical,
title = {{Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update}},
author = {Huang, Li‐Kai and Kuan, Yi‐Chun and Lin, Ho-Wei and Hu, Chaur‐Jong},
journal = {Journal of Biomedical Science},
year = {2023},
volume = {30},
number = {1},
pages = {83},
doi = {10.1186/s12929-023-00976-6},
url = {https://doi.org/10.1186/s12929-023-00976-6}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 4 | |
| 2024 | 109 | |
| 2025 | 100 | |
| 2026 | 69 |
Its field-weighted citation impact is 7.69: it has been cited 7.69 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- clinical trials
- new drug development
- aducanumab
- lecanemab
- disease-modifying therapy
- amyloid accumulation
- neuroinflammation
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Huang, L., Kuan, Y., Lin, H.-W., & Hu, C. (2023). Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update. Journal of Biomedical Science, 30(1), 83. https://doi.org/10.1186/s12929-023-00976-6
How many times has this paper been cited?
282 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Journal of Biomedical Science.
Who wrote this paper?
Li‐Kai Huang, Yi‐Chun Kuan, Ho-Wei Lin, Chaur‐Jong Hu.
What is the DOI of this paper?
10.1186/s12929-023-00976-6. The permanent link is https://doi.org/10.1186/s12929-023-00976-6.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.